

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Serum IFAT and real-time PCR results in dogs affected by *Leishmania infantum*: evaluation before and after treatment at different clinical stages**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1684708> since 2024-01-22T09:17:44Z

*Published version:*

DOI:10.1177/1040638718824140

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1    **Serum IFA and real-time PCR results in dogs affected by *Leishmania infantum*: evaluation**  
2    **before and after treatment at different clinical stages**

3

4    Barbara Bruno,<sup>1</sup> Angelo Romano, Renato Zanatta, Simona Spina, Walter Mignone, Francesco  
5    Ingravalle, Paola Barzanti, Lara Ceccarelli, Maria Goria

6

7    Department of Veterinary Science (Bruno, Zanatta), University of Turin, Torino, Italy; Istituto  
8    Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta (Romano, Spina, Mignone,  
9    Ingravalle, Barzanti, Ceccarelli, Goria), Torino, Italy.

10

11    <sup>1</sup>Corresponding author: Barbara Bruno, Department of Veterinary Science, University of Turin,  
12    Largo Paolo Braccini 2-5, 10095 Grugliasco, Torino, Italy. [barbara.bruno@unito.it](mailto:barbara.bruno@unito.it)

13

14    Running head: Changes of IFAT and real-time PCR in dogs with leishmaniasis

15

**Abstract.** We compared results of a serum immunofluorescence assay (IFA) and lymph node quantitative PCR (qPCR) in dogs classified as exposed, infected, or sick because of leishmaniasis. We also determined how IFA or qPCR changed in response to treatment and reflected different clinical and clinicopathologic improvement of dogs. We included 108 dogs in our retrospective study: 12 exposed, 25 infected, and 71 sick, as classified according to Canine Leishmaniasis Working Group standards. Between-group comparison showed higher IFA values ( $p < 0.01$ ) for sick dogs; qPCR values were higher for sick than infected dogs ( $p < 0.01$ ). A novel clinical and clinicopathologic score was created and applied to 50 sick dogs. Using this score, 41 were reclassified as partially recovered (PR) within 3 mo, and 37 as totally recovered (TR) 3-6 mo after presentation. Statistically significant differences in IFA values were found between the sick and TR dogs ( $p < 0.01$ ), but not between sick and PR dogs ( $p = 0.98$ ). During follow-up, qPCR revealed a progressive decrease in parasite load, with a statistically significant difference in sick versus PR ( $p < 0.01$ ), sick versus TR ( $p < 0.01$ ), and PR versus TR ( $p < 0.01$ ) dogs. A decrease of 1 point in the clinical score corresponded to 1.3 *Leishmania*/μL qPCR decrease ( $p < 0.01$ ) and decrease of 1:42 in IFA ( $p < 0.01$ ). Our findings confirm that the clinical status of dogs affected by leishmaniasis is closely related to parasite load and antibody level, both before and after treatment.

**Key words:** Clinical score; dog; IFA; leishmaniasis; qPCR.

36 Canine leishmaniasis (CanL) is a zoonotic disease caused by the protozoan parasite *Leishmania*  
37 *infantum*. Dogs are the main peridomestic reservoir for this organism in the Mediterranean basin.  
38 Host immune response is the most important factor for efficiently controlling parasite infection.  
39 Clinical features of infection vary widely because of the various pathogenic mechanisms involved  
40 in the disease process. Diagnosing CanL is extremely challenging as a result of nonspecific clinical  
41 presentations.<sup>3,11</sup>

42 Two guidelines for clinical classification of infected dogs, proposed by LeishVet<sup>16</sup> and by the  
43 Canine Leishmaniasis Working Group (CLWG),<sup>9</sup> can aid in establishing a diagnosis, correlating  
44 infection classes with treatment and prognosis.<sup>13,15</sup> The CLWG classification<sup>9</sup> divides dogs into 3  
45 classes (exposed, infected, and sick) based on positive serology, parasitologic analysis, and the  
46 presence or absence of clinical signs, including laboratory abnormalities suggestive of  
47 leishmaniasis. The guidelines indicate therapeutic protocols and follow-up evaluations but are less  
48 clear about how to interpret laboratory test results for monitoring response to therapy and  
49 progression of associated chronic diseases such as proteinuric nephropathy and chronic renal  
50 failure.<sup>8,16</sup> Currently, an objective method does not exist to evaluate the clinical and laboratory  
51 improvements of dogs after therapy, and to identify early changes compatible with disease  
52 recurrence.

53 The techniques used most commonly in the diagnosis of *Leishmania* infection are the indirect  
54 immunofluorescent assay (IFA), which measures the humoral antibody response, and PCR for  
55 direct identification of protozoal DNA in tissues.<sup>9,10</sup> Studies have shown correlation of humoral  
56 response, clinical status, and tissue parasite density,<sup>1,2,5,12,14,18</sup> and have evaluated the ability of  
57 ELISA, IFA, or PCR to monitor therapeutic response.<sup>2,14,17</sup> If treatment is successful, antibody titer  
58 and parasite loads decrease with time; however, contradictory results are reported for early or late  
59 declines in antibody titer and its usefulness to monitor treatment.<sup>14,17</sup>

60 We compared IFA and quantitative PCR (qPCR) values in dogs in the 3 classification groups:  
61 exposed, infected, or sick. We also determined how IFA or qPCR results changed in response to  
62 treatment and reflected different degrees of clinicopathologic improvement of dogs.

63 We reviewed the medical records of all dogs examined at our Veterinary Hospital at Turin  
64 University, Grugliasco, Torino, Italy, between 2010 and 2015. Dogs included in our study were  
65 privately owned, brought to the hospital for suspected *Leishmania infantum* infection or routine  
66 checkup, and had both IFA and qPCR performed.

67 Our Institutional Ethical and Animal Welfare Committee did not require study approval given  
68 the observational nature of the study. The owners of all dogs examined at our hospital had  
69 consented to diagnostic procedures proposed by the attending veterinarians.

70 The clinicopathologic data collected included: physical examination findings, complete blood  
71 count (ADVIA 120 Hematology, Siemens Healthcare Diagnostics, Tarrytown, NY), biochemical  
72 profile and urine protein:creatinine ratio (ILAB 300 plus, Clinical Chemistry System,  
73 Instrumentation Laboratories, Milan, Italy), serum protein electrophoresis, urinalysis (Multistix 10  
74 SG Reagent Strips, Siemens Healthcare Diagnostics), and urine sediment analysis.

75 Testing for *Leishmania infantum*, including serologic IFA and qPCR assay, was carried out  
76 by an external laboratory (Istituto Zooprofilattico Sperimentale of Piemonte, Liguria and Valle  
77 d'Aosta, Torino, Italy). Samples for qPCR and cytologic evaluation were obtained by fine-needle  
78 lymph node aspiration upon presentation. We included dogs testing positive by IFA or qPCR at the  
79 first visit in our study. Based on these test results, the dogs were classified as *exposed* if they had  
80 negative qPCR findings, positive antibody titer, and were clinically normal or did not have clinic  
81 signs associated with leishmaniasis. Dogs were classified as *infected* if they had positive qPCR  
82 findings, a positive antibody titer, and were healthy or did not have clinical signs associated with  
83 leishmaniasis. *Sick* dogs had positive qPCR findings, a positive antibody titer, and one or more  
84 clinical signs common to leishmaniasis were present.<sup>9</sup>

IFA was performed as described in the World Organization for Animal Health Manual of Diagnostic Tests and Vaccines for Terrestrial Animals.<sup>20</sup> Anti-leishmania antibodies were detected with the use of anti-dog IgG conjugated to fluorescein isothiocyanate (Sigma-Aldrich, St. Louis, MO).

For the qPCR assay, 1 mL of each lymph node aspirate was centrifuged at  $16,000 \times g$  for 5 min. The pellet was resuspended in 100  $\mu$ L of lysis kit buffer and then processed for total genomic DNA extraction (Illustra tissue and cells genomic Prep Mini Spin Kit, GE Healthcare Bio-Sciences, Pittsburgh, PA) according to the manufacturer's instructions. Three replicates of 6 DNA concentrations ( $10^3/\mu$ L to  $10^9/\mu$ L) in 10-fold serial dilutions obtained from a culture of *L. infantum* (MON-1 IPT1; provided by the National Reference Centre for Leishmaniasis, Istituto Zooprofilattico Sperimentale della Sicilia, Palermo, Italy) were used to evaluate the qPCR assay sensitivity and efficiency. The purified DNA concentration was determined by UV spectrophotometer (GeneQuant Pro, Amersham Biosciences, Buckinghamshire, UK) and normalized to 40 ng/ $\mu$ L. TaqMan probe, PCR primers, master mix concentrations, and thermal profile were used as described previously.<sup>19</sup> DNA samples were amplified in a thermocycler (CFX96 Touch Real-Time PCR Detection System, Bio-Rad, Hercules, CA). All samples were tested in triplicate. A negative control (DNA-free water) and the 6 DNA concentrations were included in each run. The results were expressed as parasites per  $\mu$ L.

All laboratory analyses performed at the initial diagnosis (CBC, biochemical profile, urine protein:creatinine ratio and urinalysis, serum protein electrophoresis, IFA, and qPCR) were repeated at subsequent follow-up visits. A novel clinicopathologic score (Table 1) was created and used to score each patient before initiation of therapy and at each visit.<sup>9</sup> This score was based on previously reported scores, and was created to provide a more comprehensive clinical-pathologic assessment.<sup>4-7,12</sup> The most common clinical signs reported in the literature and laboratory alterations useful for the monitoring and prognosis were included, and were assigned a value that increased depending on the severity of change. The score was created to be an objective value at each follow-up, creating a

111 continuous variable based on clinical evaluation. Response to therapy consistent with current  
112 guidelines was evaluated for the sick dogs that began treatment.<sup>8</sup> Prophylaxis for sandflies with  
113 synthetic pyrethroids (spot-on or collar) applied every month, was prescribed for all dogs. Treated  
114 dogs with partial improvement in clinical signs and laboratory abnormalities, defined as a decrease  
115 of 1 score point on  $\geq 50\%$  of the parameters in the novel scoring system, were classified as *partially*  
116 *recovered* (PR). Dogs with complete regression of clinical signs and laboratory abnormalities  
117 defined as when all score parameters in the novel scoring system returned to 0, were classified as  
118 *totally recovered* (TR). Dogs with chronic diseases (e.g., proteinuric nephropathy, chronic renal  
119 failure, arthropathy, or permanent ocular disease), were classified as TR although the  
120 clinicopathologic score was  $> 0$ . In these latter cases, the residual clinical and laboratory  
121 abnormalities composing the clinicopathologic score were related to irreversible injury resulting  
122 from chronic illness.

123 Statistical analysis was performed (Stata v.14, StataCorp, College Station, TX). An ANOVA  
124 was used to compare the results of initial IFA (exposed vs. infected vs. sick) and qPCR values  
125 (infected vs. sick), or a Mann-Whitney test when underlying assumptions for an ANOVA were  
126 absent. Bonferroni correction was applied to correct for multiple comparisons. To evaluate the  
127 effect of treatment and because of repeated measures on the same patient, a quantile multivariate  
128 regression model was used to identify a correlation between IFA values and clinical status (i.e.,  
129 sick, PR, TR), and a random-effects model for panel data was used to identify a correlation between  
130 qPCR values and clinical status. A random-effects model for panel data, if the underlying  
131 assumptions were met, or a quantile multivariate regression model if not, was used to identify  
132 differences in scores between the sick, PR, and TR dogs. A linear regression model was applied to  
133 identify correlations between IFA and qPCR in comparison to the clinicopathologic score, without  
134 considering the clinical status or patient age (covariates). To compare the IFA and qPCR values  
135 before and after treatment in sick dogs, an ANOVA with Bonferroni multiple-comparison

136 correction was used if underlying assumptions were met, and if not the Mann-Whitney test was  
137 applied. Statistical significance was set at 5% ( $p \leq 0.05$ ).

138 There were 108 dogs with positive IFAT and/or qPCR that qualified for inclusion in our study.  
139 There were 60 males (36 intact, 24 neutered) and 48 females (33 intact, 15 spayed), 1-15-y-old  
140 (median 7-y-old). Breed distribution was 45% mixed-breed, 6% Segugio Italiano, 5% Labrador  
141 Retriever, and 44% other breeds. Based on IFA, qPCR, clinical score, and laboratory evaluation at  
142 first visit, 12 dogs were classified as exposed, 25 as infected, and 71 as sick (Table 2). There was no  
143 significant difference in IFA values between exposed and infected dogs ( $p = 0.09$ ), whereas IFAT  
144 values were significantly higher for the sick dogs ( $p < 0.01$ ) (Table 2, Fig. 1). qPCR values were  
145 significantly higher in sick dogs compared to infected dogs ( $p < 0.01$ ) (Table 2, Fig. 1).

146 Fifty of the 71 sick dogs received treatment: allopurinol alone in 8 of 50, allopurinol and  
147 meglumine antimoniate combined in 5 of 50, and allopurinol and miltefosine combined in 37 of 50.  
148 Of these 50 sick dogs, 41 were classified as PR on follow-up visit 30-90 d after the end of  
149 treatment, and 37 as TR on follow-up visit 90-180 d after completion of treatment (Table 3).

150 The quantile multivariate regression model showed statistically significant differences in IFAT  
151 values among the 3 groups, with lower values for TR dogs than the sick ( $p < 0.01$ ) and the PR ( $p <$   
152  $0.01$ ) dogs, but no differences between the PR and the sick dogs ( $p = 0.98$ ). Analysis of qPCR  
153 results by a random-effects model showed a progressive decrease in parasitic load from sick to TR  
154 dogs, with a statistically significant difference at every follow-up assessment visit [sick versus PR  
155 ( $p < 0.01$ ), sick versus TR ( $p < 0.01$ ), and PR versus TR ( $p < 0.01$ )].

156 The linear regression model used to test the relationship between the total score and the IFA and  
157 qPCR value showed an inverse linear relation such that a decrease of 1 score point corresponded to  
158 an average decrease of 1.3 *Leishmania*/μL qPCR ( $p < 0.01$ ) and an average decrease of 1:42 in IFA  
159 ( $p < 0.01$ ). IFA values for the PR and the TR dogs were higher than those for the exposed and the  
160 infected dogs (PR vs. exposed:  $p < 0.01$ ; PR vs. infected:  $p < 0.01$ ; TR vs. exposed:  $p < 0.05$ ; TR vs.  
161 infected:  $p < 0.01$ ). qPCR values for the TR dogs were lower than those for the infected dogs ( $p <$



162 0.01), whereas no statistically significant difference in qPCR values was found between the PR and  
163 infected dogs ( $p = 0.95$ ) (Fig. 1).

164 As expected, important differences in qPCR and IFA values were found between the dogs  
165 classified as sick versus those classified as exposed or infected. The median IFA values were 10 and  
166 30 times higher in sick dogs compared to the exposed and the infected dogs respectively, and 16  
167 times higher than the maximum laboratory reference range (IFA 1:80), without overlap between  
168 groups (Fig. 1). Despite the marked differences between symptomatic and asymptomatic dogs,  
169 some sick dogs were noted to have very low IFA values (1 dog had 1:80 and 2 dogs had 1:160).  
170 Because not all dogs seroconvert after infection,<sup>10</sup> a very high antibody titer could be consistent  
171 with leishmaniasis, whereas a low titer may need further evaluation to confirm disease, such as the  
172 tissue identification of parasites.<sup>9,15</sup>

173 The median qPCR value for the sick dogs was 900 times greater than that for the infected dogs,  
174 with minimal overlap between groups at higher values. Dogs with clinical signs suggestive of  
175 leishmaniasis have significantly higher parasite loads than infected dogs. As reported in previous  
176 studies, parasite load and antibody titer are related to the severity of leishmaniasis and the degree of  
177 clinical and pathologic abnormalities.<sup>4,12</sup>

178 For the second objective of our study, dogs were reclassified as PR or TR based on clinical and  
179 laboratory improvements after therapy. To standardize and objectively evaluate dogs affected by  
180 leishmaniasis, the most common clinical and laboratory alterations reported in the literature were  
181 combined with a numeric value to create a score.<sup>9,15</sup> The advantage of this score, compared with  
182 those reported previously,<sup>4-7,12</sup> is the combination of clinical signs and laboratory alterations typical  
183 of leishmaniasis that is applicable in dogs with different clinical presentations, including those  
184 without dermatologic signs or with minimal laboratory abnormalities. Reduction in clinical signs  
185 corresponded to a significant decrease in parasite load, with an average decrease of 1.3  
186 *Leishmania*/μL for each point decrease in score. The correlation with qPCR makes the proposed

187 clinicopathologic score useful for monitoring sick dogs, and provides the clinician with an objective  
188 tool to measure improvement and suggest a trend in parasitic load.

189 The dogs with total remission of clinical and laboratory abnormalities had significantly lower  
190 qPCR values than the infected dogs. After treatment, a marked decrease in parasite load usually  
191 indicates effective control of disease but not parasitologic cure in *Leishmania* infection, because  
192 most dogs remain infected for life. Even dogs with a qPCR of zero can have fluctuations in parasite  
193 burden over time (data not shown).<sup>2,8</sup> However, a progressive increase in parasite load detected in  
194 the follow-up visit by serial monitoring of qPCR could potentially identify a dog at risk of relapse.  
195 Further studies to evaluate this possibility are warranted.

196 There was also a direct correlation between antibody level and clinicopathologic score, with an  
197 average decrease of 1:42 of IFA for each score point. It has been reported that a decrease in parasite  
198 load is revealed early by PCR assay in dogs responding to treatment, whereas antibody titers have  
199 demonstrated contrasting results. Some studies have found that it is not useful to monitor antibody  
200 levels soon after treatment because a significant decrease is seen only after 6 mo. A 2016 article  
201 reported a considerable decrease in ELISA titer as early as 30 d of therapy in dogs treated with  
202 meglumine antimoniate and allopurinol.<sup>17</sup> Our study showed no difference in IFA values between  
203 the sick and the PR dogs, although the TR dogs had a significantly lower antibody level than either  
204 of the other 2 groups. We also noted that the antibody level took time to decrease after treatment.  
205 Our findings may differ because we used a different method to measure the IgG antibody level (IFA  
206 versus ELISA), and the majority of our dogs were treated with miltefosine, which can take longer to  
207 result in clinical improvement.<sup>6</sup>

208 Our study has several limitations, including its retrospective design with incomplete follow-up  
209 data (not all sick dogs could be classified as PR or TR), multiple therapeutic regimens, and non-  
210 standardized follow-up examination after completion of therapy. Another limitation is the lack of  
211 long-term data on how many PR dogs reached TR status, at what time, and how many relapsed.

212 Our findings indicate that the clinical and pathologic status of dogs affected by leishmaniasis is  
213 closely related to parasite load and antibody level both before and after treatment. However, a  
214 decrease in the clinicopathologic score in PR was associated with a significant decrease in qPCR  
215 values whereas a difference in IFA titer was not found between PR and sick dogs. This  
216 clinicopathologic score could potentially provide guidance on patients' parasite burden while  
217 monitoring the effect of treatment. Prospective studies that track the performance of this novel  
218 clinical score, IFA, and qPCR in dogs with a relapse should be pursued.

#### 219 **Declaration of conflicting interests**

220 The authors declared no potential conflicts of interest with respect to the research, authorship,  
221 and/or publication of this article.

#### 222 **Funding**

223 The authors received no financial support for the research, authorship, and/or publication of this  
224 article.

#### 225 **References**

- 226 1. De Freitas JC, et al. Profile of anti-*Leishmania* antibodies related to clinical picture in canine  
227 visceral leishmaniasis. Res Vet Sci 2012;93:705-709.
- 228 2. Francino O, et al. Advantages of real-time PCR assay for diagnosis and monitoring of canine  
229 leishmaniosis. Vet Parasitol 2006;137:214-221.
- 230 3. Koutinas AF, et al. Clinical considerations on canine visceral leishmaniasis in Greece: a  
231 retrospective study of 158 cases (1989-1996). J Am Anim Hosp Assoc 1999;35:376-383.
- 232 4. Manna L, et al. Evidence for a relationship between *Leishmania* load and clinical manifestations.  
233 Res Vet Sci 2009a; 87:76-78.
- 234 5. Manna L, et al. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J  
235 2009b;182:441-445.
- 236 6. Manna L, et al. Long-term follow-up of dogs with leishmaniosis treated with meglumine  
237 antimoniate plus allopurinol versus miltefosine plus allopurinol. Parasit Vectors 2015;8:289.

238 7. Miró G, et al. Multicentric, controlled clinical study to evaluate effectiveness and safety of  
239 miltefosine and allopurinol for canine leishmaniosis. *Vet Dermatol* 2009;20:397-404.

240 8. Oliva G, et al. Guidelines for treatment of leishmaniasis in dogs. *J Am Vet Med Assoc* 2010;  
241 236:1192-1198.

242 9. Paltrinieri S, et al., Canine Leishmaniasis Working Group, Italian Society of Veterinarians of  
243 Companion Animals. Guidelines for diagnosis and clinical classification of leishmaniasis in  
244 dogs. *J. Am Vet Med Assoc* 2010;236:1184-1191.

245 10. Paltrinieri S, et al. Laboratory tests for diagnosing and monitoring canine leishmaniasis. *Vet*  
246 *Clin Pathol* 2016;45:552-578.

247 11. Pinelli E, et al. Cellular and humoral immune responses in dogs experimentally and naturally  
248 infected with *Leishmania infantum*. *Infect Immun* 1994;62:229-235.

249 12. Proverbio D, et al. Relationship between *Leishmania* IFAT titer and clinicopathological  
250 manifestations (clinical score) in dogs. *Biomed Res Int* 2014;2014:1-5.

251 13. Roura X, et al. Prognosis and monitoring of leishmaniasis in dogs: a working group report. *Vet*  
252 *J* 2013;198:43-47.

253 14. Solano-Gallego L, et al. *Leishmania infantum*-specific IgG, IgG1 and IgG2 antibody responses  
254 in healthy and ill dogs from endemic areas. Evolution in the course of infection and after  
255 treatment. *Vet Parasitol* 2001b;96:265-276.

256 15. Solano-Gallego L, et al. Directions for the diagnosis, clinical staging, treatment and prevention  
257 of canine leishmaniosis. *Vet Parasitol* 2009;165:1-18.

258 16. Solano-Gallego L, et al., The LeishVet Group. LeishVet guidelines for the practical  
259 management of canine leishmaniosis. *Parasit Vectors* 2011;4:86.

260 17. Solano-Gallego L, et al. Early reduction of *Leishmania infantum*-specific antibodies and blood  
261 parasitemia during treatment in dogs with moderate or severe disease. *Parasit Vectors*  
262 2016;9:235.

- 263 18. Teixeira Neto RG, et al. Relationship of *Leishmania*-specific IgG levels and IgG avidity with  
264 parasite density and clinical signs in canine leishmaniasis. Vet Parasitol 2010;169:248-257.
- 265 19. Vitale F, et al. TaqMan-based detection of *Leishmania infantum* DNA using canine samples.  
266 Ann NY Acad Sci 2004;1026:139-43.
- 267 20. World Organisation for Animal Health (OIE): Leishmaniosis. Manual of Diagnostic Tests and  
268 Vaccines for Terrestrial Animals 2012;240-250.
- 269

270 **Table 1.** Novel clinicopathologic scoring system for dogs with suspected *Leishmania infantum*  
271 infection.

	Score			
Finding	0	1	2	3
Appetite	Normal	Dysorexia	Anorexia	Anorexia
Decreased performance	No	Mild	Moderate	Severe
Lameness	No	Occasional episodes	Recurrent episodes	Persistent
Gastrointestinal signs (vomiting or diarrhea)	No	Occasional episodes	Recurrent episodes	Persistent
Epistaxis	No	Single episode	Recurrent episodes	Persistent bleeding
Mucous membrane	Pink	Congested	Pale	White
Muscle atrophy	No	Localized	Multifocal	Generalized
Lymphadenopathy	No	Mild	Moderate	Severe
Body condition score (5= normal)	5	4	3	2
Cutaneous ulcers	No	Localized	Multifocal	Generalized
Cutaneous crusts	No	Localized	Multifocal	Generalized
Alopecia	No	Localized	Multifocal	Generalized
Onychogryphosis	No	Mild	Moderate	Severe
Dandruff	No	Localized	Multifocal	Generalized
Hyperkeratosis	No	Mild	Moderate	Severe
Cutaneous nodules	No	Localized	Multifocal	Generalized
Uveitis	No	Mild	Moderate	Severe
Conjunctivitis	No	Mild	Moderate	Severe
Hematocrit (L/L)	>0.37	0.3-0.36	0.2-0.29	<0.2
Platelets (x10 <sup>9</sup> /L)	>200	200-51	50-20	<20
Creatinine (μmol/L) (mg/dl)	<124 (<1.4)	124-168 (1.4-1.9)	169-442 (2-5)	>442 (>5)
UPC (with inactive sediment)	< 0.2	0.2- 0.49	0.5 - 2	>2
Total protein g/L (g/dL)	55-75 (5.5 – 7.5)	76-84 (7.6 – 8.4)	85-95 (8.5 – 9.5)	95 (>9.5)
Albumin g/L (g/dL)	35-30 (3.5-3)	29-25 (2.9-2.5)	24.9-20 (2.49-2.0)	<20 (<2)
Gamma globulins g/L (g/dL)	4-8 (0.4-0.8)	8.1-13 (0.81-1.3)	14-25 (1.4-2.5)	>26 (>2.6)
A/G ratio	≥0.6	0.4-0.59	0.21-0.39	<0.2

272

273 A/G = albumin to globulin ratio; Hct = hematocrit; UPC = urine protein to creatinine ratio with  
274 original units as mg/dL.  
275 Occasional episodes = 1 or 2 episodes/mo; Persistent = > 1 episode/wk; Recurrent episodes = 1  
276 episode/wk;  
277 Generalized = >3 sites affected; Localized = 1 site affected; Multifocal = 2 or 3 sites affected.  
278

279 **Table 2.** IFA and qPCR values at presentation of 108 dogs exposed to *Leishmania infantum*. Dogs  
 280 were classified as exposed, infected, or sick based on IFA, qPCR, and on our leishmaniasis  
 281 clinicopathologic score.

	Exposed ( <i>n</i> = 12)	Infected ( <i>n</i> = 25)	Sick ( <i>n</i> = 71)
IFA	1:120 * (1:80-1:640)	1:40 ** (1:20-1:2,560)	1:1,280 (1:80-1:40,960)
qPCR ( <i>Leishmania</i> /μL)	0	0.01 # (0.001-16)	9 (0.001-1,000)

282  
 283 Numbers = median (minimum-maximum). IFA = immunofluorescence assay; qPCR = quantitative  
 284 PCR; \*comparison of IFA values between exposed and sick dogs ( $p = 0.0001$ ); \*\*comparison of  
 285 IFAT values between infected and sick dogs ( $p = 0.0001$ ); #comparison of qPCR values between  
 286 infected and sick dogs ( $p = 0.0001$ ).

287



288 **Table 3.** Follow-up IFA and qPCR values of 50 sick dogs infected with *Leishmania infantum* after  
 289 treatment. Dogs with chronic disease were classified as total remission although the  
 290 clinicopathologic score was > 0, because of irreversible injury resulting from chronic illness.

Treated dogs ( <i>n</i> = 50)	Sick dogs ( <i>n</i> = 50)	PR ( <i>n</i> = 41)	TR ( <i>n</i> = 37)
IFA	1:1,280 (1:80-1:40,960)	1:1,280 (1:320-1:40,960)	1:320 ** (1:20-1:5,120)
qPCR ( <i>Leishmania</i> /μL)	7.25 (0.001-1,000)	0.033 * (0-109)	0.005 *# (0-2.8)

291

292 IFA = immunofluorescence assay; Numbers = median (minimum-maximum); PR = partial  
 293 remission (decrease of 1 score point on ≥ 50% of the parameters of scoring system recorded as  
 294 abnormal at the time of diagnosis); qPCR = quantitative PCR; TR = total remission (all score  
 295 parameters returned to 0). \*\*comparison of IFAT values between TR and sick dogs (*p* = 0.006);  
 296 \*comparison of qPCR values between TR (*p* = 0.0001), PR (*p* = 0.0001) and sick dogs;  
 297 #comparison of qPCR values between PR and TR dogs (*p* = 0.004).

298

299 **Figure 1.** Box plot of the logarithmic distribution of IFA and qPCR values in the 3 groups of 108  
 300 dogs at presentation: 12 exposed, 25 infected, 71 sick dogs, and in the 2 subgroups of 50 sick  
 301 animals following treatment at 2 different times (PR, TR). **A.** Box plot of the logarithmic  
 302 distribution of IFA values in dogs at presentation. **B.** Box plot of the logarithmic distribution of  
 303 qPCR values in dogs at presentation. **C.** Box plot of logarithmic distribution of IFAT values in dogs  
 304 after treatment (subgroups PR and TR). **D.** Box plot of logarithmic distribution of qPCR values in  
 305 dogs after treatment (subgroups PR and TR).  
 306 IFA = indirect immunofluorescent assay; qPCR = quantitative PCR (*Leishmania*/μL); PR = dogs  
 307 with partial remission; TR = dogs with total remission. Dots in qPCR figures were values of higher  
 308 than the upper whiskers. The upper whiskers are called “upper adjacent value” and are defined as  
 309  $x_{[75]} + 1.5(x_{[75]} - x_{[25]})$ , where:  $x_{[75]}$  = 3<sup>rd</sup> quartile;  $x_{[25]}$  = 1<sup>st</sup> quartile. \*IFA comparison: sick dogs vs  
 310 exposed ( $p = 0.0001$ ), infected ( $p = 0.0001$ ), PR ( $p = 0.98$ ) and TR ( $p = 0.006$ ); qPCR comparison:  
 311 sick dogs vs infected ( $p = 0.0001$ ), PR ( $p = 0.0001$ ) and TR ( $p = 0.0001$ ).§IFA comparison: exposed  
 312 dogs vs PR ( $p = 0.0001$ ) and TR ( $p = 0.005$ ). †IFA comparison: infected dogs vs PR ( $p = 0.0001$ )  
 313 and TR ( $p = 0.001$ ). #qPCR comparison TR vs PR ( $p = 0.004$ ).